Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00284804 | A Phase II Study of MDX-060 in Subjects With Relapsed or Refractory Hodgkin's Disease | PHASE2 | COMPLETED | 74 | — | — | Nov 1, 2005 | Oct 1, 2009 | Oct 12, 2015 | 17 | United States |
| Arm | Type | Description |
|---|---|---|
| MDX-060 plus standard of care | EXPERIMENTAL | MDX-060 in combination with gemcitabine |
| Standard of care | ACTIVE_COMPARATOR | Gemcitabine |
| Name | Type | Description |
|---|---|---|
| MDX-060 | DRUG | anti-CD30 monoclonal antibody, i.v. weekly x 3 10 mg/kg |
Inclusion Criteria: * Diagnosis of Hodgkin's disease \[HD\] (excluding HIV-associated HD) * Patients must have read, understood, and provided written informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization after the nature of the study has been fully explained...